AN EFFICACY, SAFETY, AND PHARMACOKINETICS STUDY OF SUBCUTANEOUSLY ADMINISTERED USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS IN PEDIATRIC PARTICIPANTS GREATER THAN OR EQUAL TO 6 TO LESS THAN 12 YEARS OF AGE: